Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BFRI

Biofrontera Inc.

Healthcare | Drug Manufacturers - Specialty & Generic
$1.19
Market Cap$10M
Volume56.1K
EPS (TTM)$-0.46

Biofrontera Inc. (NASDAQ: BFRI) is a $10M drug manufacturers - specialty & generic company trading at $1.19. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:44 UTC.

What Biofrontera Inc. does

Biofrontera is a United States-based biopharmaceutical company that develops, manufactures, and sells pharmaceutical products for treating dermatological conditions, particularly using photodynamic therapy. The company's main products are Ameluz and the RhodoLED Lamp series, which are used to treat actinic keratosis, a common skin condition with pre-cancerous lesions. Biofrontera sells these products directly to dermatology offices and groups through a national commercial team.

Summarized from Biofrontera Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$1.19
Market cap$10M
Volume56.1K shares
Valuation
EPS (TTM)$-0.46
Price/book0.95×

Revenue, margins & earnings

FY2021: net loss $38M on revenue $24M$24MFY2021FY2022: net loss $640,000 on revenue $29M$29MFY2022FY2023: net loss $20M on revenue $34M$34MFY2023FY2024: net loss $18M on revenue $37M$37MFY2024FY2025: net loss $11M on revenue $42M$42MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-29
  • 2026-07-29CEO & ChairmanOption exercise62,500—
  • 2026-07-29CEO & ChairmanOption exercise-62,500—
  • 2026-07-29Chief Financial OfficerOption exercise31,250—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Biofrontera Inc. do?

Biofrontera is a United States-based biopharmaceutical company that develops, manufactures, and sells pharmaceutical products for treating dermatological conditions, particularly using photodynamic therapy.

What is BFRI's valuation?

BFRI trades at $1.19, as of 2026-10-11.

When did BFRI last file with the SEC?

Biofrontera Inc.'s most recent SEC filing on record is a 10-K/A filed 2026-07-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:44 UTC. This page is also available as JSON at /api/data?ticker=BFRI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BFRI and 5,000+ tickers.

Create a free account — keep BFRI
For your agent
GET /api/data?ticker=BFRI

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt